{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:22:37Z","timestamp":1761855757318,"version":"build-2065373602"},"reference-count":23,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005703","name":"Akdeniz \u00dcniversitesi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005703","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the National Medical Association"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.jnma.2020.03.012","type":"journal-article","created":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T00:25:01Z","timestamp":1586996701000},"page":"250-257","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effects of Different Immunosuppressive Drugs on Incretins in Renal Transplant Patients"],"prefix":"10.1016","volume":"112","author":[{"given":"Nusret","family":"Yilmaz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramazan","family":"Sari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gultekin","family":"Suleymanlar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebahat","family":"Ozdem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 2","key":"10.1016\/j.jnma.2020.03.012_bib1","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/S1262-3636(08)73397-4","article-title":"Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes","volume":"34","author":"Gautier","year":"2008","journal-title":"Diabetes Metab"},{"issue":"3","key":"10.1016\/j.jnma.2020.03.012_bib2","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cmet.2006.01.004","article-title":"The biology of incretin hormones","volume":"3","author":"Drucker","year":"2006","journal-title":"Cell Metabol"},{"issue":"1","key":"10.1016\/j.jnma.2020.03.012_bib3","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.pharmthera.2009.06.002","article-title":"Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors","volume":"124","author":"Verspohl","year":"2009","journal-title":"Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.jnma.2020.03.012_bib4","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1136\/gut.2004.059741","article-title":"Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans","volume":"55","author":"Schirra","year":"2006","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.jnma.2020.03.012_bib5","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1210\/jcem.87.3.8355","article-title":"Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers","volume":"87","author":"Nauck","year":"2002","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.jnma.2020.03.012_bib6","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1210\/jcem.86.8.7743","article-title":"Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes","volume":"86","author":"Toft-Nielsen","year":"2001","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"9309","key":"10.1016\/j.jnma.2020.03.012_bib7","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(02)07952-7","article-title":"Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study","volume":"359","author":"Zander","year":"2002","journal-title":"Lancet"},{"issue":"5 Pt 1","key":"10.1016\/j.jnma.2020.03.012_bib8","first-page":"E981","article-title":"Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans","volume":"273","author":"Nauck","year":"1997","journal-title":"Am J Physiol"},{"issue":"9","key":"10.1016\/j.jnma.2020.03.012_bib9","first-page":"4382","article-title":"A\u00a0meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans","volume":"86","author":"Verdich","year":"2001","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"Suppl 3","key":"10.1016\/j.jnma.2020.03.012_bib10","doi-asserted-by":"crossref","first-page":"S190","DOI":"10.2337\/diabetes.53.suppl_3.S190","article-title":"Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes","volume":"53","author":"Nauck","year":"2004","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.jnma.2020.03.012_bib11","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1210\/jcem-63-2-492","article-title":"Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses","volume":"63","author":"Nauck","year":"1986","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.jnma.2020.03.012_bib12","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.2337\/db07-0100","article-title":"Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state?","volume":"56","author":"Knop","year":"2007","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.jnma.2020.03.012_bib13","doi-asserted-by":"crossref","first-page":"583","DOI":"10.2337\/diacare.25.3.583","article-title":"Posttransplantation diabetes: a systematic review of the literature","volume":"25","author":"Montori","year":"2002","journal-title":"Diabetes Care"},{"issue":"10 suppl l","key":"10.1016\/j.jnma.2020.03.012_bib14","article-title":"New-onset diabetes after transplantation: 2003 International consensus guidelines","volume":"75","author":"Davidson","year":"2003","journal-title":"Transplantation"},{"issue":"8","key":"10.1016\/j.jnma.2020.03.012_bib15","doi-asserted-by":"crossref","first-page":"833","DOI":"10.3727\/096368909X471198","article-title":"Different effects of FK506, rapamycin, and mycophenolate mofetil on glucose-stimulated insulin release and apoptosis in human islets","volume":"18","author":"Johnson","year":"2009","journal-title":"Cell Transplant"},{"issue":"9","key":"10.1016\/j.jnma.2020.03.012_bib16","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1172\/JCI32959","article-title":"Recovery from diabetes in mice by beta cell regeneration","volume":"117","author":"Nir","year":"2007","journal-title":"J\u00a0Clin Invest"},{"issue":"3","key":"10.1016\/j.jnma.2020.03.012_bib17","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/00007890-200202150-00007","article-title":"Inhibitory effects of immunosuppressive drugs on insulin secretion from HIT-T15 cells and Wistar rat islets","volume":"73","author":"Paty","year":"2002","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.jnma.2020.03.012_bib18","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s005920200039","article-title":"Secretory defects induced by immunosuppressive agents on human pancreatic beta-cells","volume":"39","author":"Polastri","year":"2002","journal-title":"Acta Diabetol"},{"issue":"10","key":"10.1016\/j.jnma.2020.03.012_bib19","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1007\/s00125-006-0374-5","article-title":"The impact of the mTOR inhibitor sirolimus on the proliferation and function of pancreatic islets and ductal cells","volume":"49","author":"Bussiere","year":"2006","journal-title":"Diabetologia"},{"issue":"6","key":"10.1016\/j.jnma.2020.03.012_bib20","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1097\/01.TP.0000079833.86120.85","article-title":"Impaired insulin response after oral but not intravenous glucose in heart- and liver-transplant recipients","volume":"76","author":"Henchoz","year":"2003","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.jnma.2020.03.012_bib21","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1210\/jc.2010-2435","article-title":"Impaired regulation of the incretin effect in patients with type 2 diabetes","volume":"96","author":"Bagger","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.jnma.2020.03.012_bib22","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/nmo.12150","article-title":"Glucose-induced incretin hormone release and insulin sensitivity are impaired in patients with idiopathic gastroparesis: results from a pilot descriptive study","volume":"25","author":"Prevost","year":"2013","journal-title":"Neuro Gastroenterol Motil"},{"issue":"3","key":"10.1016\/j.jnma.2020.03.012_bib23","doi-asserted-by":"crossref","first-page":"654","DOI":"10.2337\/diabetes.53.3.654","article-title":"Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects","volume":"53","author":"Meier","year":"2004","journal-title":"Diabetes"}],"container-title":["Journal of the National Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0027968420300596?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0027968420300596?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T06:17:27Z","timestamp":1758435447000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0027968420300596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S0027968420300596"],"URL":"https:\/\/doi.org\/10.1016\/j.jnma.2020.03.012","relation":{},"ISSN":["0027-9684"],"issn-type":[{"type":"print","value":"0027-9684"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of Different Immunosuppressive Drugs on Incretins in Renal Transplant Patients","name":"articletitle","label":"Article Title"},{"value":"Journal of the National Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jnma.2020.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the National Medical Association. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}